British officials remain optimistic, but Health Minister Matt Hancock is calling on Thursday 27 May “To alert” : The number of cases in version B1.617.2 (first detected in India) has doubled again in a week in the United Kingdom, now reaching about 7,000 cases listed. These figures are very modest, yet the trend is worrying: “New positive cases between half and three quarters are due to version B1.617.2”, Mr. Hancock added to a conference in Downing Street.
“This version is becoming prominent [dans le pays] », Added Jenny Harris, head of the UK’s health agency, “This progress is continuing but we don’t know if it’s because it’s spreading or it’s because we’re doing more testing in areas where it’s spreading” The expert adds cautiously. It is now present across the country, including London, but the center of infection is in the northwest of England – Greater manchester – and to some extent in the Midlands. The densely populated areas (Bolton, Blackburn or Leicester), where a significant portion of the population live in multi-generation homes, perform service work, making teleworking impossible. And many are residents of the Indian subcontinent: the first people who were infected with the version B.1.617.2 returned directly from India.
In some places, the reluctance of the vaccine persists.
In these areas the British Government sent troops for ten days to assist in quick vaccination of the population – “We are in a vaccine race against the variant”, Mr. Hancock insisted. The British vaccination campaign is moving at a very good pace, now 24 million people have been fully vaccinated (about a third of the population). In addition, according to a study by the National Statistics Office (ONS), three-quarters of adults in the UK have antibodies to the novel coronavirus.
But in some places (London, for example), and in certain categories of the population (especially among black people or people of Asian descent), reluctance to vaccinate persists, even though the British Immunization Authority (JCVI) introduced Decided in the month of May to limit the use of the Oxford-AstraZeneca vaccine for people over the age of 40, to assure the risks of developing cerebral thrombosis, which is extremely rare but higher in young people Times occur.
You have 51.21% of this article to read. The rest is for subscribers.